MoFo News Item

MoFo Advises Augmedix in Uplisting to Nasdaq and $40 Million Underwritten Public Offering

29 Oct 2021

Morrison & Foerster advised Augmedix, Inc., a leading provider of virtual medical documentation and live clinical support, in connection with the company’s underwritten public offering of 10 million shares of its common stock at a public offering price of $4 per share. Augmedix’s common stock began trading on the Nasdaq under the symbol “AUGX” on October 26, 2021.

Augmedix offers virtual medical documentation and live clinical support to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine practices nationwide. Its Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes, and provides a suite of related services. Augmedix plans to use the net proceeds it receives from the offering to fund increased investment in sales and marketing, research and development, and general and administrative costs as Augmedix increases its scale.

The MoFo deal team advising Augmedix was led by San Francisco corporate partner John Rafferty, New York corporate partner John Owen, Washington, D.C. partner David Lynn, Washington, D.C. associate Mary Katherine Rawls, and San Francisco associate Ken Taylor.

Read more about the transaction in Augmedix’s press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.